The capital will support ongoing clinical trials in multiple locations and advance development for Lung Therapeutics’ “transformative” drug for fibrosis, LTI-03.
The company has now raised $17 million in outside funding, aside from the $27 million awarded for discovery research and development.
The latest raise was headed by Bios Partners, a life sciences private equity firm out of Dallas and Fort Worth, Texas.
More articles on supply chain:
Mylan keeps EpiPen costs high despite intense public scrutiny
6 FDA decisions to keep an eye on in June
C-suites containing supply chain leaders have better operational performance: 7 survey insights
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
